Willow

'Gumball Dreams' to have its International Premiere at the 79th Venice International Film Festival

Retrieved on: 
Friday, August 5, 2022 - 1:26am

Falling through memories, Onyx reveals the music of the spheres and the nature of existence, as you fly through worlds both inner & outer.

Key Points: 
  • Falling through memories, Onyx reveals the music of the spheres and the nature of existence, as you fly through worlds both inner & outer.
  • Organised by La Biennale di Venezia and directed by Alberto Barbera, the 79th Venice International Film Festival (www.labiennale.org/en/cinema/2022) will take place at the Venice Lido from 31 August to 10 September 2022.
  • And I'm endlessly grateful to the founders and curators of the festival for bringing us together in this way."
  • A powerful and intimate experience that allows us to discover a mythic world beyond the reaches of our reality.

Bausch Health Provides Update Following Oral Order in XIFAXAN® Patent Litigation

Retrieved on: 
Thursday, July 28, 2022 - 8:45pm

LAVAL, Quebec, July 28, 2022 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC), and its gastroenterology business Salix Pharmaceuticals, today announced the U.S. District Court of Delaware issued an Oral Order in the matter of Salix Pharmaceuticals, Ltd. et al v. Norwich Pharmaceuticals, Inc. regarding the infringement and validity of certain U.S. Patents protecting the composition and use of XIFAXAN® (rifaximin) 550 mg tablets for the treatment of irritable bowel syndrome with diarrhea (IBS-D) and reduction in risk of overt hepatic encephalopathy (HE) recurrence.

Key Points: 
  • When the Court enters a final order, Bausch Health will consider all available options to vigorously defend the intellectual property protecting XIFAXAN and will appeal the Court's decision to the U.S. Court of Appeals for the Federal Circuit.
  • We strongly disagree with any conclusion that our patents are not valid and intend to file an appeal to any such order," Thomas J. Appio, CEO, Bausch Health, said.
  • The Company intends to file an appeal immediately after any final order is issued, assuming it is consistent with the Oral Order.
  • Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global diversified pharmaceutical company whose mission is to improve people's lives with our health care products.

Willow Industries Appoints Scott Daly as Chief Commercial Officer

Retrieved on: 
Wednesday, July 27, 2022 - 12:00pm

DENVER, July 27, 2022 /PRNewswire/ -- Willow Industries Inc., the leader in cannabis kill-step and decontamination technology, is pleased to announce the appointment of Scott Daly as Chief Commercial Officer. In this role, Scott will oversee the development and execution of the go to market commercial strategy to accelerate Willow's exponential growth across new and existing markets.

Key Points: 
  • DENVER, July 27, 2022 /PRNewswire/ -- Willow Industries Inc. , the leader in cannabis kill-step and decontamination technology, is pleased to announce the appointment of Scott Daly as Chief Commercial Officer.
  • In this role, Scott willoversee the development and execution of the go to market commercial strategy to accelerate Willow's exponential growth across new and existing markets.
  • Scott joins Willow with more than 25 years of executive leadership experience in the technology and cannabis industries, with significant expertise in strategic planning, start-up business development, and rapid growth business strategies.
  • Prior to joining the team, Scott served as the Chief Revenue Officer at Simplifya, a regulatory compliance solutions company for the cannabis industry.

BLP Acquires Off-Market Industrial Property - Marks 21st Deal and $789 Million Closed Since Initial Investment Seven Months Ago

Retrieved on: 
Monday, July 18, 2022 - 2:00pm

In the seven months that BLP has been investing on behalf of institutional investors, the logistics real estate company has closed 21 deals.

Key Points: 
  • In the seven months that BLP has been investing on behalf of institutional investors, the logistics real estate company has closed 21 deals.
  • At the same time, the expanding e-commerce economy is deepening demand for these facilities and creating a backdrop for further value appreciation.
  • With the support of marquee global institutional investors, they have quickly amassed a sizeable industrial real estate portfolio totaling 3.9 million square feet.
  • BLP has a pipeline of another $1.8 billion of assets under agreement totaling an additional 10.6 million square feet.

WILLOW BIOSCIENCES APPOINTS DR. PETER SEUFER-WASSERTHAL AS INTERIM PRESIDENT AND CEO

Retrieved on: 
Monday, July 18, 2022 - 12:00pm

In addition to the above mentioned changes, Ms. Barbara Munroe, a Director of the Company, has been appointed as Lead Independent Director.

Key Points: 
  • In addition to the above mentioned changes, Ms. Barbara Munroe, a Director of the Company, has been appointed as Lead Independent Director.
  • "Peter is a visionary leader that has been Chairman of the Board of Willow since 2020," said Barbara Munroe.
  • We are grateful for his contributions to Willow and wish him all the best in his retirement."
  • "I am enthused to take over as Interim CEO at such an exciting time in the Company's history," said Dr. Peter Seufer-Wasserthal.

Salix Announces 2022 Gastrointestinal Health Scholars Program Winners

Retrieved on: 
Wednesday, July 13, 2022 - 12:00pm

LAVAL, QC, July 13, 2022 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and its gastroenterology business, Salix Pharmaceuticals, ("Salix"), one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal (GI) and liver diseases and disorders, today announced the winners of its 2022 Salix Gastrointestinal Health Scholars Program. For the third consecutive year, Salix will be awarding $10,000 each to 10 students living with a GI disease.

Key Points: 
  • LAVAL, QC, July 13, 2022 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and its gastroenterology business, Salix Pharmaceuticals, ("Salix"), one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal (GI) and liver diseases and disorders, todayannounced the winners of its 2022 Salix Gastrointestinal Health Scholars Program.
  • "Salix is pleased to recognize these 10 outstanding Salix Gastrointestinal Health Scholarship awardees who are thriving in their academic journey while living with the challenges of a gastrointestinal condition," said Nicola Kayel, vice president, Marketing, Salix.
  • The 2022 Salix Gastrointestinal Health Scholars Program recipients are:
    "It's hard to express my gratitude and how grateful I truly am for this opportunity," said Joshua Swimmer, a recipient of the Working Parent's Award and a student at the University of Southern Indiana.
  • To learn more about the Salix Gastrointestinal Health Scholars Program, visit www.salix.com/scholarship .

WILLOW BIOSCIENCES INCORPORATES INSCRIPTA'S ONYX® PLATFORM TO EXPAND STRAIN ENGINEERING CAPABILITIES AND THROUGHPUT

Retrieved on: 
Monday, June 6, 2022 - 12:00pm

When used in this news release, the words "will," "anticipate," "believe," "estimate," "expect," "intent," "may," "project," "should," and similar expressions are intended to be among the statements that identify forward-looking statements.

Key Points: 
  • When used in this news release, the words "will," "anticipate," "believe," "estimate," "expect," "intent," "may," "project," "should," and similar expressions are intended to be among the statements that identify forward-looking statements.
  • Projected operational information contains forward-looking information and is based on a number of material assumptions and factors, as are set out above.
  • These projections may also be considered to contain future-oriented financial information or a financial outlook.
  • The forward-looking statements contained herein are expressly qualified by this cautionary statement.

PGT Trucking Recognizes 182 Drivers at Annual Million Mile & Safe Driver Celebration

Retrieved on: 
Thursday, June 2, 2022 - 7:30pm

"It is an honor and a privilege to recognize our Million Mile and Safe Drivers," stated Pat Gallagher, PGT Trucking CEO.

Key Points: 
  • "It is an honor and a privilege to recognize our Million Mile and Safe Drivers," stated Pat Gallagher, PGT Trucking CEO.
  • PGT's Safe Drivers have driven for the company for more than five years, but less than one million miles, without a safety incident, and Million Mile Drivers have accomplished this pristine status by driving over a million miles without a safety incident.
  • PGT has recognized its Million Mile and Safe Drivers for more than 20 years, and the Million Mile and Safe Driver Celebration is the leading event for PGT drivers, office staff and their guests.
  • "Once again, our Million Mile and Safe Drivers prove their professionalism and excellent job performance in an extremely difficult environment," acknowledged Gregg Troian, PGT Trucking President.

WILLOW BIOSCIENCES EXPANDS ITS PORTFOLIO WITH A NEW PARTNERED PHARMACEUTICAL PROJECT

Retrieved on: 
Tuesday, May 31, 2022 - 12:00pm

"This is a significant step forward in the evolution of Willow's business", said Trevor Peters, Willow's President and Chief Executive Officer.

Key Points: 
  • "This is a significant step forward in the evolution of Willow's business", said Trevor Peters, Willow's President and Chief Executive Officer.
  • As Willow continues to expand its capabilities and add new partnerships, Willow is on a path to becoming the premier name in biobased manufacturing."
  • The project consists of research & development and commercialization phases, with revenue coming from both research fees and milestone payments.
  • Willow develops and produces high-purity ingredients for the personal care, food and beverage, and pharmaceutical markets.

WILLOW BIOSCIENCES ANNOUNCES EXPANSION OF ITS FERMENTATION MANUFACTURING NETWORK AND PROGRESS ON ITS CBG GRAS DETERMINATION

Retrieved on: 
Wednesday, May 11, 2022 - 9:01pm

This new CDMO partnership allows Willow to accommodate new programs, both internal and partnered, in addition to its cannabinoid portfolio.

Key Points: 
  • This new CDMO partnership allows Willow to accommodate new programs, both internal and partnered, in addition to its cannabinoid portfolio.
  • Willow has successfully completedthe Stage 1toxicological assessment of its FutureGrown CBG product for oral product applications, an important milestone for biosynthetically produced cannabinoids.
  • The assessment concluded that FutureGrownTM CBG was non-mutagenic, non-clastogenic, non-genotoxic, which, is the first step toward concluding Willow's FutureGrown CBG as GRAS in the United States.
  • Willow produces its FutureGrown CBG through precision fermentation, drastically reducing production time and carbon footprint when compared to traditionally grown cannabis extracts.